請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69976
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 梁碧惠 | zh_TW |
dc.contributor.advisor | Pi-Hui Liang | en |
dc.contributor.author | 王筱雯 | zh_TW |
dc.contributor.author | Hsiao-Wen Wang | en |
dc.date.accessioned | 2021-06-17T03:36:56Z | - |
dc.date.available | 2023-12-07 | - |
dc.date.copyright | 2018-03-29 | - |
dc.date.issued | 2018 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 1. Torchilin, V. P., Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9 (2), E128-47.
2. Parveen, S.; Misra, R.; Sahoo, S. K., Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine : nanotechnology, biology, and medicine 2012, 8 (2), 147-66. 3. Bamrungsap, S.; Zhao, Z.; Chen, T.; Wang, L.; Li, C.; Fu, T.; Tan, W., Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine : nanotechnology, biology, and medicine 2012, 7 (8), 1253-71. 4. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C., Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83 (5), 761-9. 5. Kasongo, K. W.; Shegokar, R.; Muller, R. H.; Walker, R. B., Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex. Drug Dev. Ind. Pharm. 2011, 37 (4), 396-407. 6. Griffith, L. G., Polymeric biomaterials. Acta Materialia 2000, 48 (1), 263-277. 7. Drummond, D. C.; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadjopoulos, D., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51 (4), 691-743. 8. Zununi Vahed, S.; Salehi, R.; Davaran, S.; Sharifi, S., Liposome-based drug co-delivery systems in cancer cells. Mater. Sci. Eng C Mater. Biol. Appl. 2017, 71, 1327-1341. 9. Kuijpers, S. A.; Coimbra, M. J.; Storm, G.; Schiffelers, R. M., Liposomes targeting tumour stromal cells. Molecular membrane biology 2010, 27 (7), 328-40. 10. Misra, R.; Acharya, S.; Sahoo, S. K., Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov. Today 2010, 15 (19-20), 842-50. 11. Ju, R. J.; Zeng, F.; Liu, L.; Mu, L. M.; Xie, H. J.; Zhao, Y.; Yan, Y.; Wu, J. S.; Hu, Y. J.; Lu, W. L., Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. Int. J. Nanomedicine 2016, 11, 1131-1146. 12. Ruttala, H. B.; Ko, Y. T., Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids Surf. B Biointerfaces 2015, 128, 419-426. 13. Sun, L.; Zhou, D. S.; Zhang, P.; Li, Q. H.; Liu, P., Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma. Int. J. Pharm. 2015, 478 (1), 308-317. 14. Zhao, G.; Lin, H., Metal Complexes with Aromatic N-Containing Ligands as Potential Agents in Cancer Treatment. Curr. Med. Chem. Anticancer Agents 2005, 5 (2), 137-147. 15. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K., Antitumour metal compounds: more than theme and variations. Dalton Trans. 2008, (2), 183-194. 16. Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J., Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun. 2005, (38), 4764-4776. 17. Weiss, R. B.; Christian, M. C., New Cisplatin Analogues in Development. Drugs 1993, 46 (3), 360-377. 18. Criado, J. J.; Manzano, J. L.; Rodrı́guez-Fernández, E., New organotropic compounds: Synthesis, characterization and reactivity of Pt(II) and Au(III) complexes with bile acids: DNA interactions and ‘in vitro’ anticancer activity. J. Inorg. Biochem. 2003, 96 (2), 311-320. 19. Lee, S. M.; O'Halloran, T. V.; Nguyen, S. T., Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J. Am. Chem. Soc. 2010, 132 (48), 17130-8. 20. Dai, X.; Tan, C., Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers. Adv. Drug Deliv. Rev. 2015, 81, 184-197. 21. Shim, G.; Kim, M.-G.; Park, J. Y.; Oh, Y.-K., Application of cationic liposomes for delivery of nucleic acids. Asian J. Pharm. Sci. 2013, 8 (2), 72-80. 22. Yu, Y. H.; Kim, E.; Park, D. E.; Shim, G.; Lee, S.; Kim, Y. B.; Kim, C.-W.; Oh, Y.-K., Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm. 2012, 80 (2), 268-273. 23. He, Z.; Yu, Y.; Zhang, Y.; Yan, Y.; Zheng, Y.; He, J.; Xie, Y.; He, G.; Wei, Y.; Song, X., Gene Delivery with Active Targeting to Ovarian Cancer Cells Mediated by Folate Receptor alpha. J. Biomed. Nanotechnol. 2013, 9 (5), 833-844. 24. Seymour, L. W.; Ferry, D. R.; Anderson, D.; Hesslewood, S.; Julyan, P. J.; Poyner, R.; Doran, J.; Young, A. M.; Burtles, S.; Kerr, D. J., Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20 (6), 1668-76. 25. Mattheolabakis, G.; Milane, L.; Singh, A.; Amiji, M. M., Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J. Drug Target. 2015, 23 (7-8), 605-618. 26. Qian, Z. M.; Li, H.; Sun, H.; Ho, K., Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54 (4), 561-87. 27. Accardo, A.; Morelli, G., Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues. Pept. Sci. 2015, 104 (5), 462-479. 28. Bozzuto, G.; Molinari, A., Liposomes as nanomedical devices. Int. J. Nanomedicine 2015, 10, 975-99. 29. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54 (4), 987-92. 30. Batist, G., Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol. 2007, 7 (2), 72-74. 31. Petre, C. E.; Dittmer, D. P., Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int. J. Nanomedicine 2007, 2 (3), 277-88. 32. Forssen, E. A.; Coulter, D. M.; Proffitt, R. T., Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992, 52 (12), 3255-61. 33. Forssen, E. A.; Ross, M. E., Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations. J. Liposome Res. 1994, 4 (1), 481-512. 34. Harris, L.; Batist, G.; Belt, R.; Rovira, D.; Navari, R.; Azarnia, N.; Welles, L.; Winer, E.; Group, T. D. S., Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94 (1), 25-36. 35. Cowens, J. W.; Creaven, P. J.; Greco, W. R.; Brenner, D. E.; Tung, Y.; Ostro, M.; Pilkiewicz, F.; Ginsberg, R.; Petrelli, N., Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993, 53 (12), 2796-802. 36. Balazsovits, J. A. E.; Mayer, L. D.; Bally, M. B.; Cullis, P. R.; McDonell, M.; Ginsberg, R. S.; Falk, R. E., Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 1989, 23 (2), 81-86. 37. Glantz, M. J.; Jaeckle, K. A.; Chamberlain, M. C.; Phuphanich, S.; Recht, L.; Swinnen, L. J.; Maria, B.; LaFollette, S.; Schumann, G. B.; Cole, B. F.; Howell, S. B., A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999, 5 (11), 3394-402. 38. Drummond, D. C.; Noble, C. O.; Guo, Z.; Hong, K.; Park, J. W.; Kirpotin, D. B., Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer research 2006, 66 (6), 3271-7. 39. Kipps, E.; Young, K.; Starling, N., Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther. Adv. Med. Oncol. 2017, 9 (3), 159-170. 40. Janoff, A. S.; Perkins, W. R.; Saletan, S. L.; Swenson, C. E., Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities. J. Liposome Res. 1993, 3 (3), 451-471. 41. Adler-moore, J. P.; Proffitt, R. T., Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B. J. Liposome Res. 1993, 3 (3), 429-450. 42. Walsh, T. J.; Yeldandi, V.; McEvoy, M.; Gonzalez, C.; Chanock, S.; Freifeld, A.; Seibel, N. I.; Whitcomb, P. O.; Jarosinski, P.; Boswell, G.; Bekersky, I.; Alak, A.; Buell, D.; Barret, J.; Wilson, W., Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 1998, 42 (9), 2391-8. 43. Guo, L. S. S.; Fielding, R. M.; Lasic, D. D.; Hamilton, R. L.; Mufson, D., Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 1991, 75 (1), 45-54. 44. Fielding, R. M.; Singer, A. W.; Wang, L. H.; Babbar, S.; Guo, L. S., Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 1992, 36 (2), 299-307. 45. Sanders, S. W.; Buchi, K. N.; Goddard, M. S.; Lang, J. K.; Tolman, K. G., Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 1991, 35 (6), 1029-34. 46. Alam, M.; Hartrick, C. T., Extended-release epidural morphine (DepoDur): an old drug with a new profile. Pain Pract. 2005, 5 (4), 349-53. 47. Chappuis, F.; Farinelli, T.; Deckx, H.; Sarnecki, M.; Go, O.; Salzgeber, Y.; Stals, C., Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine 2017, 35 (10), 1448-1454. 48. Gluck, R.; Metcalfe, I. C., New technology platforms in the development of vaccines for the future. Vaccine 2002, 20 Suppl 5, B10-6. 49. Conne, P.; Gauthey, L.; Vernet, P.; Althaus, B.; Que, J. U.; Finkel, B.; Gluck, R.; Cryz, S. J., Jr., Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997, 15 (15), 1675-9. 50. Yokomichi, N.; Nagasawa, T.; Coler-Reilly, A.; Suzuki, H.; Kubota, Y.; Yoshioka, R.; Tozawa, A.; Suzuki, N.; Yamaguchi, Y., Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin. Hum. Cell 2013, 26 (1), 8-18. 51. Tocanne, J. F.; Cezanne, L.; Lopez, A.; Piknova, B.; Schram, V.; Tournier, J. F.; Welby, M., Lipid domains and lipid/protein interactions in biological membranes. Chem. Phys. Lipids 1994, 73 (1-2), 139-58. 52. Mouritsen, O. G., Model answers to lipid membrane questions. Cold Spring Harb Perspect Biol. 2011, 3 (9), a004622. 53. Andersen, O. S.; Koeppe, R. E., 2nd, Bilayer thickness and membrane protein function: an energetic perspective. Annu. Rev. Biophys. Biomol. Struct. 2007, 36, 107-30. 54. Frost, A.; Unger, V. M.; De Camilli, P., The BAR domain superfamily: membrane-molding macromolecules. Cell 2009, 137 (2), 191-6. 55. Monteiro, N.; Martins, A.; Reis, R. L.; Neves, N. M., Liposomes in tissue engineering and regenerative medicine. Journal of the Royal Society, Interface 2014, 11 (101), 20140459. 56. Almeida, P. F., Biochim. Biophys. Acta. Biochimica et biophysica acta 2009, 1788 (1), 72-85. 57. Cybulski, L. E.; del Solar, G.; Craig, P. O.; Espinosa, M.; de Mendoza, D., Bacillus subtilis DesR functions as a phosphorylation-activated switch to control membrane lipid fluidity. J. Biol. Chem. 2004, 279 (38), 39340-7. 58. Mansilla, M. C.; Cybulski, L. E.; Albanesi, D.; de Mendoza, D., Control of membrane lipid fluidity by molecular thermosensors. J. Bacteriol. 2004, 186 (20), 6681-8. 59. Yeagle, P. L., Cholesterol and the cell membrane. Biochim. Biophys. Acta 1985, 822 (3-4), 267-87. 60. McMahon, H. T.; Gallop, J. L., Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature 2005, 438 (7068), 590-6. 61. Jouhet, J., Importance of the hexagonal lipid phase in biological membrane organization. Front. Plant Sci. 2013, 4, 494. 62. Gruner, S. M., Intrinsic curvature hypothesis for biomembrane lipid composition: a role for nonbilayer lipids. Proc. Natl. Acad. Sci. U. S. A. 1985, 82 (11), 3665-9. 63. de Kruijff, B., Biomembranes. Lipids beyond the bilayer. Nature 1997, 386 (6621), 129-30. 64. Chen, Y. F.; Tsang, K. Y.; Chang, W. F.; Fan, Z. A., Differential dependencies on [Ca2+] and temperature of the monolayer spontaneous curvatures of DOPE, DOPA and cardiolipin: effects of modulating the strength of the inter-headgroup repulsion. Soft matter 2015, 11 (20), 4041-53. 65. Subczynski, W. K.; Pasenkiewicz-Gierula, M.; Widomska, J.; Mainali, L.; Raguz, M., High Cholesterol/Low Cholesterol: Effects in Biological Membranes: A Review. Cell Biochem. Biophys. 2017, 75 (3-4), 369-385. 66. Subczynski, W. K.; Hyde, J. S.; Kusumi, A., Effect of alkyl chain unsaturation and cholesterol intercalation on oxygen transport in membranes: a pulse ESR spin labeling study. Biochemistry 1991, 30 (35), 8578-90. 67. Bagatolli, L. A.; Parasassi, T.; Gratton, E., Giant phospholipid vesicles: comparison among the whole lipid sample characteristics using different preparation methods: a two photon fluorescence microscopy study. Chem. Phys. Lipids 2000, 105 (2), 135-47. 68. Bagatolli, L. A.; Needham, D., Quantitative optical microscopy and micromanipulation studies on the lipid bilayer membranes of giant unilamellar vesicles. Chem. Phys. Lipids 2014, 181, 99-120. 69. Gamblin, S. J.; Haire, L. F.; Russell, R. J.; Stevens, D. J.; Xiao, B.; Ha, Y.; Vasisht, N.; Steinhauer, D. A.; Daniels, R. S.; Elliot, A.; Wiley, D. C.; Skehel, J. J., The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science (New York, N.Y.) 2004, 303 (5665), 1838-42. 70. Nycholat, C. M.; McBride, R.; Ekiert, D. C.; Xu, R.; Rangarajan, J.; Peng, W.; Razi, N.; Gilbert, M.; Wakarchuk, W.; Wilson, I. A.; Paulson, J. C., Recognition of sialylated poly-N-acetyllactosamine chains on N- and O-linked glycans by human and avian influenza A virus hemagglutinins. Angew. Chem. Int. Ed. 2012, 51 (20), 4860-3. 71. Marin, M. J.; Rashid, A.; Rejzek, M.; Fairhurst, S. A.; Wharton, S. A.; Martin, S. R.; McCauley, J. W.; Wileman, T.; Field, R. A.; Russell, D. A., Glyconanoparticles for the plasmonic detection and discrimination between human and avian influenza virus. Org. Biomol. Chem. 2013, 11 (41), 7101-7. 72. Nazemi, A.; Haeryfar, S. M.; Gillies, E. R., Multifunctional dendritic sialopolymersomes as potential antiviral agents: their lectin binding and drug release properties. Langmuir : the ACS journal of surfaces and colloids 2013, 29 (21), 6420-8. 73. Sigal, G. B.; Mammen, M.; Dahmann, G.; Whitesides, G. M., Polyacrylamides Bearing Pendant α-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions. J. Am. Chem. Soc. 1996, 118 (16), 3789-3800. 74. DeFrees, S. A.; Phillips, L.; Guo, L.; Zalipsky, S., Sialyl Lewis x Liposomes as a Multivalent Ligand and Inhibitor of E-Selectin Mediated Cellular Adhesion. J. Am. Chem. Soc. 1996, 118 (26), 6101-6104. 75. Meyer, S. C.; Miers, L. J., Cardiovascular surgeon and acute care nurse practitioner: collaboration on postoperative outcomes. AACN Clin. Issues 2005, 16 (2), 149-58. 76. Cheng, H.-W. Study on sialyllacto-N-tetrasaccharide c (LSTc)-bearing liposomal synthesis and anti-influenza A Virus. National Taiwan University, 2014. 77. Wilson, J. C.; Kiefel, M. J.; Angus, D. I.; von Itzstein, M., Investigation of the stability of thiosialosides toward hydrolysis by sialidases using NMR spectroscopy. Org. Lett. 1999, 1 (3), 443-6. 78. Yeh, H. W.; Lin, T. S.; Wang, H. W.; Cheng, H. W.; Liu, D. Z.; Liang, P. H., S-Linked sialyloligosaccharides bearing liposomes and micelles as influenza virus inhibitors. Org. Biomol. Chem. 2015, 13 (47), 11518-28. 79. Stevens, J.; Blixt, O.; Glaser, L.; Taubenberger, J. K.; Palese, P.; Paulson, J. C.; Wilson, I. A., Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 2006, 355 (5), 1143-55. 80. Chandrasekaran, A.; Srinivasan, A.; Raman, R.; Viswanathan, K.; Raguram, S.; Tumpey, T. M.; Sasisekharan, V.; Sasisekharan, R., Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat. Biotechnol. 2008, 26 (1), 107-13. 81. Harris, A. K.; Meyerson, J. R.; Matsuoka, Y.; Kuybeda, O.; Moran, A.; Bliss, D.; Das, S. R.; Yewdell, J. W.; Sapiro, G.; Subbarao, K.; Subramaniam, S., Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (12), 4592-7. 82. Alves, D.; Olívia Pereira, M., Mini-review: Antimicrobial peptides and enzymes as promising candidates to functionalize biomaterial surfaces. Biofouling 2014, 30 (4), 483-499. 83. Fjell, C. D.; Hiss, J. A.; Hancock, R. E.; Schneider, G., Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 2011, 11 (1), 37-51. 84. Chamakura, K. R.; Sham, L. T.; Davis, R. M.; Min, L.; Cho, H.; Ruiz, N.; Bernhardt, T. G.; Young, R., A viral protein antibiotic inhibits lipid II flippase activity. Nat. Microbiol. 2017, 2 (11), 1480-1484. 85. Typas, A.; Banzhaf, M.; Gross, C. A.; Vollmer, W., From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat. Rev. Microbiol. 2011, 10 (2), 123-36. 86. Vollmer, W.; Seligman, S. J., Architecture of peptidoglycan: more data and more models. Trends Microbiol. 2010, 18 (2), 59-66. 87. Barreteau, H.; Kovac, A.; Boniface, A.; Sova, M.; Gobec, S.; Blanot, D., Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol. Rev. 2008, 32 (2), 168-207. 88. Bouhss, A.; Trunkfield, A. E.; Bugg, T. D.; Mengin-Lecreulx, D., The biosynthesis of peptidoglycan lipid-linked intermediates. FEMS Microbiol. Rev. 2008, 32 (2), 208-33. 89. Sanyal, S.; Menon, A. K., Flipping lipids: why an' what's the reason for? ACS Chem. Biol. 2009, 4 (11), 895-909. 90. Pomorski, T.; Menon, A. K., Lipid flippases and their biological functions. Cell. Mol. Life Sci. 2006, 63 (24), 2908-21. 91. de Pedro, M. A.; Donachie, W. D.; Holtje, J. V.; Schwarz, H., Constitutive septal murein synthesis in Escherichia coli with impaired activity of the morphogenetic proteins RodA and penicillin-binding protein 2. J. Bacteriol. 2001, 183 (14), 4115-26. 92. Khattar, M. M.; Begg, K. J.; Donachie, W. D., Identification of FtsW and characterization of a new ftsW division mutant of Escherichia coli. J. Bacteriol. 1994, 176 (23), 7140-7. 93. Henriques, A. O.; Glaser, P.; Piggot, P. J.; Moran, C. P., Jr., Control of cell shape and elongation by the rodA gene in Bacillus subtilis. Mol. Microbiol. 1998, 28 (2), 235-47. 94. Mohammadi, T.; van Dam, V.; Sijbrandi, R.; Vernet, T.; Zapun, A.; Bouhss, A.; Diepeveen-de Bruin, M.; Nguyen-Disteche, M.; de Kruijff, B.; Breukink, E., Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J. 2011, 30 (8), 1425-32. 95. Hvorup, R. N.; Winnen, B.; Chang, A. B.; Jiang, Y.; Zhou, X. F.; Saier, M. H., Jr., The multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) exporter superfamily. Eur. J. Biochem. 2003, 270 (5), 799-813. 96. Ruiz, N., Bioinformatics identification of MurJ (MviN) as the peptidoglycan lipid II flippase in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (40), 15553-7. 97. Inoue, A.; Murata, Y.; Takahashi, H.; Tsuji, N.; Fujisaki, S.; Kato, J., Involvement of an essential gene, mviN, in murein synthesis in Escherichia coli. J. Bacteriol. 2008, 190 (21), 7298-301. 98. Sham, L. T.; Butler, E. K.; Lebar, M. D.; Kahne, D.; Bernhardt, T. G.; Ruiz, N., Bacterial cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science (New York, N.Y.) 2014, 345 (6193), 220-2. 99. Islam, S. T.; Lam, J. S., Synthesis of bacterial polysaccharides via the Wzx/Wzy-dependent pathway. Can. J. Microbiol. 2014, 60 (11), 697-716. 100. Islam, S. T.; Fieldhouse, R. J.; Anderson, E. M.; Taylor, V. L.; Keates, R. A.; Ford, R. C.; Lam, J. S., A cationic lumen in the Wzx flippase mediates anionic O-antigen subunit translocation in Pseudomonas aeruginosa PAO1. Mol. Microbiol. 2012, 84 (6), 1165-76. 101. Kuroda, T.; Tsuchiya, T., Multidrug efflux transporters in the MATE family. Biochim. Biophys. Acta. 2009, 1794 (5), 763-8. 102. He, X.; Szewczyk, P.; Karyakin, A.; Evin, M.; Hong, W. X.; Zhang, Q.; Chang, G., Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 2010, 467 (7318), 991-4. 103. Lu, M.; Radchenko, M.; Symersky, J.; Nie, R.; Guo, Y., Structural insights into H+-coupled multidrug extrusion by a MATE transporter. Nat. Struct. Mol. Biol. 2013, 20 (11), 1310-7. 104. Tanaka, Y.; Hipolito, C. J.; Maturana, A. D.; Ito, K.; Kuroda, T.; Higuchi, T.; Katoh, T.; Kato, H. E.; Hattori, M.; Kumazaki, K.; Tsukazaki, T.; Ishitani, R.; Suga, H.; Nureki, O., Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 2013, 496 (7444), 247-51. 105. Butler, E. K.; Tan, W. B.; Joseph, H.; Ruiz, N., Charge requirements of lipid II flippase activity in Escherichia coli. J. Bacteriol. 2014, 196 (23), 4111-9. 106. Butler, E. K.; Davis, R. M.; Bari, V.; Nicholson, P. A.; Ruiz, N., Structure-function analysis of MurJ reveals a solvent-exposed cavity containing residues essential for peptidoglycan biogenesis in Escherichia coli. J. Bacteriol. 2013, 195 (20), 4639-49. 107. Lee, A. G., How lipids affect the activities of integral membrane proteins. Biochim. Biophys. Acta 2004, 1666 (1-2), 62-87. 108. Hong, H.; Tamm, L. K., Elastic coupling of integral membrane protein stability to lipid bilayer forces. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (12), 4065-70. 109. Rigaud, J. L.; Pitard, B.; Levy, D., Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins. Biochim. Biophys. Acta 1995, 1231 (3), 223-46. 110. Kuk, A. C.; Mashalidis, E. H.; Lee, S. Y., Crystal structure of the MOP flippase MurJ in an inward-facing conformation. Nat. Struct. Mol. Biol. 2017, 24 (2), 171-176. 111. Gao, Y., Glycopeptide antibiotics and development of inhibitors to overcome vancomycin resistance. Nat. Prod. Rep. 2002, 19 (1), 100-7. 112. Huber, J.; Donald, R. G.; Lee, S. H.; Jarantow, L. W.; Salvatore, M. J.; Meng, X.; Painter, R.; Onishi, R. H.; Occi, J.; Dorso, K.; Young, K.; Park, Y. W.; Skwish, S.; Szymonifka, M. J.; Waddell, T. S.; Miesel, L.; Phillips, J. W.; Roemer, T., Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol. 2009, 16 (8), 837-48. 113. Yuan, L.; Lin, W.; Zheng, K.; Zhu, S., FRET-based small-molecule fluorescent probes: rational design and bioimaging applications. Acc. Chem. Res. 2013, 46 (7), 1462-73. 114. Sahoo, H., Förster resonance energy transfer – A spectroscopic nanoruler: Principle and applications. J. Photochem. Photobiol. C-Photochem. Rev. 2011, 12 (1), 20-30. 115. Loura, L. M.; Prieto, M., FRET in Membrane Biophysics: An Overview. Front. Physiol. 2011, 2, 82. 116. Sengupta, P.; Holowka, D.; Baird, B., Fluorescence resonance energy transfer between lipid probes detects nanoscopic heterogeneity in the plasma membrane of live cells. Biophys. J. 2007, 92 (10), 3564-74. 117. Blumenthal, R.; Gallo, S. A.; Viard, M.; Raviv, Y.; Puri, A., Fluorescent lipid probes in the study of viral membrane fusion. Chem. Phys. Lipids 2002, 116 (1-2), 39-55. 118. Matyus, L.; Szollosi, J.; Jenei, A., Steady-state fluorescence quenching applications for studying protein structure and dynamics. J. Biol. Chem. 2006, 83 (3), 223-36. 119. Möller, M.; Denicola, A., Protein tryptophan accessibility studied by fluorescence quenching. Biochem. Mol. Biol. Educ. 2002, 30 (3), 175-178. 120. Rahman, M.; Harmon, H. J., Absorbance change and static quenching of fluorescence of meso-tetra(4-sulfonatophenyl)porphyrin (TPPS) by trinitrotoluene (TNT). Spectrochim. Acta A Mol. Biomol. Spectrosc. 2006, 65 (3-4), 901-6. 121. Sapsford, K. E.; Berti, L.; Medintz, I. L., Materials for fluorescence resonance energy transfer analysis: beyond traditional donor-acceptor combinations. Angew. Chem. Int. Edn. 2006, 45 (28), 4562-89. 122. Hao, R.; Xing, R.; Xu, Z.; Hou, Y.; Gao, S.; Sun, S., Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv. Mater. 2010, 22 (25), 2729-42. 123. Wei, S.; Wang, Q.; Zhu, J.; Sun, L.; Lin, H.; Guo, Z., Multifunctional composite core-shell nanoparticles. Nanoscale 2011, 3 (11), 4474-502. 124. Ghosh Chaudhuri, R.; Paria, S., Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. Chem. Rev. 2012, 112 (4), 2373-433. 125. Ye, J.; Van de Broek, B.; De Palma, R.; Libaers, W.; Clays, K.; Van Roy, W.; Borghs, G.; Maes, G., Surface morphology changes on silica-coated gold colloids. Colloids Surf. A 2008, 322 (1), 225-233. 126. Langlois, C.; Benzo, P.; Arenal, R.; Benoit, M.; Nicolai, J.; Combe, N.; Ponchet, A.; Casanove, M. J., Fully Crystalline Faceted Fe-Au Core-Shell Nanoparticles. Nano lett. 2015, 15 (8), 5075-80. 127. Padmos, J. D.; Personick, M. L.; Tang, Q.; Duchesne, P. N.; Jiang, D. E.; Mirkin, C. A.; Zhang, P., The surface structure of silver-coated gold nanocrystals and its influence on shape control. Nat. Commun. 2015, 6, 7664. 128. Qu, Z.; Yu, F.; Zhang, X.; Wang, Y.; Gao, J., Support effects on the structure and catalytic activity of mesoporous Ag/CeO2 catalysts for CO oxidation. Chem. Eng. J. 2013, 229, 522-532. 129. Yang, F.; Huang, J.; Odoom-Wubah, T.; Hong, Y.; Du, M.; Sun, D.; Jia, L.; Li, Q., Efficient Ag/CeO2 catalysts for CO oxidation prepared with microwave-assisted biosynthesis. Chem. Eng. J. 2015, 269, 105-112. 130. Zhou, X.; Graham, T. R., Reconstitution of phospholipid translocase activity with purified Drs2p, a type-IV P-type ATPase from budding yeast. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (39), 16586-91. 131. Childs, R. A.; Palma, A. S.; Wharton, S.; Matrosovich, T.; Liu, Y.; Chai, W.; Campanero-Rhodes, M. A.; Zhang, Y.; Eickmann, M.; Kiso, M.; Hay, A.; Matrosovich, M.; Feizi, T., Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat. Biotechnol. 2009, 27 (9), 797-9. 132. Nycholat, C. M.; McBride, R.; Ekiert, D. C.; Xu, R.; Rangarajan, J.; Peng, W.; Razi, N.; Gilbert, M.; Wakarchuk, W.; Wilson, I. A.; Paulson, J. C., Recognition of sialylated poly-N-acetyllactosamine chains on N- and O-linked glycans by human and avian influenza A virus hemagglutinins. Angewandte Chemie (International ed. in English) 2012, 51 (20), 4860-3. 133. Varki, A., Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 2007, 446 (7139), 1023-9. 134. Lehmann, F.; Tiralongo, E.; Tiralongo, J., Sialic acid-specific lectins: occurrence, specificity and function. Cell. Mol. Life Sci. 2006, 63 (12), 1331-54. 135. Pastan, I.; Hassan, R.; Fitzgerald, D. J.; Kreitman, R. J., Immunotoxin therapy of cancer. Nat. Rev. Cancer 2006, 6 (7), 559-65. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69976 | - |
dc.description.abstract | 微脂體能形成人造膜的系統,用於研究蛋白質功能和藥物輸送,其組成取決於於膜的物化性質、組成成分的特性、尺寸、以及表面電荷。因此,我們利用微脂體平台來研究生物學行為和藥物輸送。
病毒與宿主細胞之間的特異性辨識是取決於兩種膜結合的糖蛋白,血凝素 (HA) 和神經氨酸酶 (NA)。 Zanamivir 和 Oseltamivir 為流感病毒的神經氨酸酶抑制劑,已被廣泛使用,目前少有關於 HA 抑制劑的研究。本論文,我們合成了含唾液酸之參醣及伍醣,也將其共價鍵結於DLPE (1,2-dilauroyl-sn-glycero-3-phosphoethanol-amine) 脂質上。這些醣脂與 DPPC (1,2-dihexadecanoyl-sn-glycero-3-phosphocholine) 和膽固醇在適當的比例混合後形成含有唾液醣之微脂體。高密度之唾液參醣在抑制 A / WSN / 33 / H1N1 流感病毒進入細胞之活性為 EC50 70-180 μM 。低密度之含唾液伍醣之微脂體則具有弱的抑制流感病毒進入人類細胞的能力,但其抑制紅血球凝集則更為增強。 由於多重抗藥性細菌的問題日益嚴重,所以發展新型抗生素是至關重要的。肽聚醣的合成過程皆為具有潛力的抗生素發展標的。在肽聚醣生合成中, MurJEC 在革蘭氏陰性菌中是保守存在的翻轉酶,其造成 Lipid II 穿過細胞質膜後提供 disaccharide-pentapeptide 單體並且產生 polymerization 和 cross-linking 而形成肽聚醣。至今僅有體內實驗證實 MurJ 能翻轉 E.coli 之 Lipid II,尚未有 MurJEC 體外重組系統的相關證據。為了模擬 Lipid II 和 MurJEC 之間的生物學相關的相互作用,我們發展一種 ”外到內” 之蛋白微脂體模型將 MurJEC 重組於單層巨型微脂體 (GUV) 中,並且證明 MurJEC 可辨識並翻轉 NBD-Lipid II(7) 。從我們的人造膜系統中,證實 GlcNAc-MurNAc 雙醣和 pyrophosphoryl-undecaprenol 會影響 MurJ 翻轉的辨識能力。 MurJ 疏水區的突變會影響運輸活性。在本研究中,我們利用 FRET-based liposome 作為能即時監測蛋白微脂體的螢光淬熄的工具。 Ag@CeO2 作為淬熄劑包覆在微脂體內部,此方式能簡化並且改進的蛋白微脂體的測定,獲得 MurJEC 翻轉 NBD-Lipid II(7) 的翻轉平衡常數 Km 為 6.7 nM,平均每個 MurJEC 蛋白每分鐘翻轉 0.1 個 NBD-Lipid II(7)。 | zh_TW |
dc.description.abstract | Liposomes provide an artificial membrane system to study protein function and drug-delivery. Development of liposomal platform needs to understand and investigate the physicochemical properties of membrane and the nature of liposomal component, as well as to fine-tune the particle size and surface change. In this thesis, two applications were conducted, 1) targeting influenza virus by sialic acid decoyed liposome, 2) development of proteoliposome to study bacterial flippase activity of Lipid II.
The specific recognition between influenza virus particles and the host cells depended on two membrane-bound glycoproteins, named hemagglutinin (HA) and neuraminidase (NA). Zanamivir and oseltamivir have been demonstrated to be potent neuraminidase inhibitors against influenza virus. Until now, very few studies have gained achievemet on HA inhibiton. Herein, both S-sialyl bearing trisaccharides and pentasaccharides were synthesised and conjugated with phospholipid-DLPE (1,2-dilauroyl-sn-glycero-3-phosphorylethanolamine). These DLPE containg oligosaccharides combined with DPPC (1,2-dihexadecanoyl-sn-glycero-3-phosphocholine) and cholesterol with appropriate molar ratio, providing sialyl-contaning liposome to target HA of influenza virus. High density of S-Neu5Ac-α2-6-LacNAc containing liposome was shown to have an EC50 of around 70-180 μM in the A / WSN / 33 / H1N1 virus entry inhibitory assay. Low density of S-Neu5Ac-α2-6-di-LacNAc containing liposome displayed weak inhibiton in virus entry inhibition, but had stronger inhibition in the hemagglutination inhibition assay. As the problem of multi-drug resistant bacteria deteriorated, the development of novel classes of antibiotics is important. Peptidoglycan synthesis pathway is an potential target for antibiotics. In peptidoglycan biogenesis, the flippase translocates Lipid II across the cytoplasmic membrane to deliver the disaccharide-pentapeptide monomer as the building block for polymerization and cross-linking. In vivo systems have demostrated MurJ as a flippase of Lipid II in the Gram(-) E.coli. None in vitro reconstitution system of MurJ has been reported. In order to investigate the interaction of Lipid II and MurJ, we developed an “out to in” proteoliposomal model in giant unilamellar vesicles (GUVs) and demonstrated that MurJ was able to recognize and transport NBD-Lipid II(7) efficiently. The substrate specificity study of NBD-Lipid II(7) towared MurJ identified that the structure of the GlcNAc–MurNAc and pyrophosphoryl-undecaprenol were required for the transport activity of the MurJ. Mutation of the hydrophobic groove of MurJ reduced the transporting activity of MurJ. Furthermore, we also developed a FRET-based liposome to monitore the transport kinetic of NBD-Lipid II(7) and MurJ. Encapsulated Ag@CeO2 as a quencher in the liposome, it allowed us to real-time monitor the translocation of NBD-Lipid II(7) by MurJ. The Km of NBD-Lipid II(7) to MurJ was 6.7 nM and maximal translocation rate was 0.1 Lipid II/min/MurJ. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:36:56Z (GMT). No. of bitstreams: 1 ntu-107-D99423006-1.pdf: 5489526 bytes, checksum: 15759a4a2612a9d1711d542bb68d484d (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員審定書 ................................ ................................ ................................ ............... i
致謝 ................................ ................................ ................................ ................................ .. ii 中文摘要 ................................ ................................ ................................ ......................... iii 英文摘要 ................................ ................................ ................................ .......................... v 英文縮寫表 ................................ ................................ ................................ ................... xiv 第一章、導論 ................................ ................................ ................................ .................. 1 1.1 微脂體為何? ................................ ................................ ................................ ........... 1 1.2 臨床前微脂體輸送系統之設計 ................................ ................................ ............... 5 1.3 上市或臨床試驗中的微脂體劑型藥物 ................................ ................................ ... 7 1.3.1 治療癌症的微脂體 ................................ ................................ ................................ 7 1.3.2 治療黴菌感染的微脂體 ................................ ................................ ........................ 8 1.3.3 緩解疼痛的微脂體 ................................ ................................ ................................ 8 1.3.4 治療病毒感染的微脂體 ................................ ................................ ........................ 8 1.4 重建生物膜系統的模型:蛋白微脂體 (Proteoliposome) ................................ .... 11 1.4.1 膜的流體特性 ................................ ................................ ................................ ....... 11 1.4.2 脂質多態性 (lipid polymorphism) ................................ ................................ ...... 13 1.4.3 膽固醇 ................................ ................................ ................................ .................. 15 1.4.4 Giant unilamellar vesicles (GUVs) ................................ ................................ ....... 16 1.5 研究動機 ................................ ................................ ................................ ................. 17 第二章、末端為唾液酸的醣分子標靶流感病毒並偵測其抑制能力 ............ 19 2.1 背景:建立標靶流感病毒的微脂體 ................................ ................................ ..... 19 2.2 結果與討 論 ................................ ................................ ................................ ............. 20 2.2.1 微脂體以 S-linked 三醣修飾表面作為標靶流感病毒載體 ............................. 20 2.2.2 微脂體以 S-linked 五醣修飾表面作為標靶流感病毒載體 ............................. 24 2.3 結論 ................................ ................................ ................................ ......................... 28 第三章、細菌胞壁的研究及膜蛋白活性探討 ................................ .................... 29 3.1 背景 ................................ ................................ ................................ ......................... 29 3.1.1 細菌胞壁的形成 ................................ ................................ .............................. 30 3.1.2 Lipid II的運輸 ................................ ................................ ................................ ...... 31 3.2 結果與討論 ................................ ................................ ................................ ............. 33 3.2.1 MurJEC 蛋白質的純化 蛋白質的純化 ................................ ................................ .......................... 33 3.2.2建立蛋白微脂粒 ................................ ................................ ................................ ... 35 3.2.3 蛋白微脂粒的影像研究 ................................ ................................ ...................... 45 3.2.4 活性實驗 ................................ ................................ ................................ .............. 47 3.2.4.1 MurJEC 與 Lipid II 的特異性結合 ................................ ................................ ... 50 3.2.4.2 Lipid II 和 Lipid II analog 與 MurJEC 的特異性結合 ................................ .. 52 3.2.4.3 突變的 MurJEC 對 Lipid II 和 Lipid II analog的影響 ................................ 53 3.2.4.4 阻斷劑 (Blocker) 的特異性作用 ................................ ................................ .... 56 3.3 結論 ................................ ................................ ................................ ......................... 59 第四章、螢光共振能量轉移的應用 ................................ ................................ ............ 60 4.1 背景 ................................ ................................ ................................ ......................... 60 4.1.1 螢光共振能量轉移 (fluorescence resonance energy transfer,FRET) ............. 60 4.1.2 淬熄效應 (Quenching effect) ................................ ................................ .............. 62 4.1.3 淬熄劑 (Quencher Molecules) ................................ ................................ ............ 63 4.1.4 奈米材料:銀 @二氧化鈰 (Ag@CeO2) 核殼結構 ................................ ........... 64 4.2 結果與討論 ................................ ................................ ................................ ............. 65 4.2.1 第一種系統 ................................ ................................ ................................ .......... 65 4.2.2 第二種系統 ................................ ................................ ................................ .......... 66 4.3 結論 ................................ ................................ ................................ ......................... 67 第五章、總結 ................................ ................................ ................................ ................ 70 5.1 末端為唾液酸的醣分子標靶流感病毒並偵測其抑制能力 ..................... 70 5.2 建立 MurJEC 蛋白微脂體並且評估 蛋白微脂體並且評估 MurJEC 翻轉 Lipid II 的效用 ................... 71 第六章、實驗部分 ................................ ................................ ................................ ........ 73 第一部分 : 末端為唾液酸的醣分子標靶流感病毒並偵測其抑制能力 ....... 73 6.1.1 三醣微脂體的製備 ................................ ................................ .............................. 73 6.1.2 五醣微脂體的製備 ................................ ................................ .............................. 74 6.1.3 病毒中和實驗 (Neutralization assay) ................................ ................................ . 74 6.1.4 血球凝集抑制實驗 (Hemagglutination inhibition assay) ................................ .. 75 第二部分 : 細菌胞壁的研究及膜蛋白活性探討 ................................ ............... 76 6.2.1重組大腸桿菌 MurJ(MurJEC)的表達和純化 )的表達和純化 ................................ .................. 76 6.2.2 蛋白質微脂體的製備 ................................ ................................ .......................... 76 6.2.3 蛋白質微脂體的活性實驗 ................................ ................................ .................. 78 6.2.3.1 NBD-Lipid II、NBD-Lipid II analog與 MurJEC 的活性實驗 ......................... 78 6.2.3.2 突變的 MurJEC 對 Lipid II 和 Lipid II analog ................................ .............. 79 6.2.3.3 NBD-Lipid II、阻斷劑與 、阻斷劑與 MurJEC 的活性實驗 的活性實驗 ................................ ................ 80 6.2.4 蛋白微脂粒的影像研究 ................................ ................................ ...................... 82 6.2.4.1 低溫三維立體穿透式電子顯微鏡 (3D Cryo-TEM) ................................ ....... 82 6.2.4.2 倒立式螢光顯微鏡 (Ti-U) ................................ ................................ ............... 83 6.2.5 化合物製備 ................................ ................................ ................................ .......... 83 第三部分 :螢光共振能量轉移( FRET)實驗 ................................ ........................... 84 6.3.1 第一種系統 ................................ ................................ ................................ .......... 84 6.3.2 第二種系統 ................................ ................................ ................................ .......... 84 第七章、相關文獻 ................................ ................................ ................................ ........ 86 | - |
dc.language.iso | zh_TW | - |
dc.title | 微脂體平台於流感病毒標靶及細菌 Lipid II 翻轉酶之研究 | zh_TW |
dc.title | Investigation of Liposomal Platform for Targeting Influenza Virus and Bacterial Lipid II Flippase Evaluation | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-1 | - |
dc.description.degree | 博士 | - |
dc.contributor.oralexamcommittee | 劉得任;陳基旺;忻凌偉;鄭偉杰 | zh_TW |
dc.contributor.oralexamcommittee | Der-Zen Liu;Ji-Wang Chern;Ling-Wei Hsin;Wei-Chieh Cheng | en |
dc.subject.keyword | 血球凝集素抑制劑,蛋白質微脂體,MurJ,Lipid-II,螢光共振能量轉移分析, | zh_TW |
dc.subject.keyword | Hemagglutinin inhibitor,proteoliposome,MurJ,Lipid-II,FRET analysis, | en |
dc.relation.page | 96 | - |
dc.identifier.doi | 10.6342/NTU201800029 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-02-12 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 藥學研究所 | - |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 5.36 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。